ELECTROPHYSIOLOGICAL AND ANTIARRHYTHMIC EFFECTS OF A NOVEL III CLASS ANTIARRHYTHMIC MANUFACTURED IN RUSSIA, NIFERIDIL COMMUNICATION II: ELECTROPHYSIOLOGICAL MECHANISMS OF ANTIARRHYTHMIC EFFECT OF NIFERIDIL IN PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIAS
Abstract
To analyze antiarrhythmic effectiveness of Niferidil in patients with paroxysmal supraventricular tachycardias and to clarify mechanisms of its curative and protective antiarrhythmic effects, 23 patients were examined.
About the Authors
N. Yu. Mironov
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
S. P. Golitsyn
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
S. F. Sokolov
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
E. B. Maykov
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
N. B. Shlevkov
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
Yu. A. Yuricheva
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
Yu. V. Mareev
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
L. V. Rozenshtraukh
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
E. I. Chazov
Институт клинической кардиологии им А.Л.Мясникова ФГБУ РКНПК МЗ РФ, Москва
Russian Federation
Russian Federation
References
1. Blomström-Lundqvist C, Scheinman MM, Aliot EM et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) // Circulation, 2003. V. 108(15). P. 1871-1909.
2. Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a metaanalysis // Eur J Emerg Med, 2011. V. 18(3). P. 148-152.
3. Rankin AC, Brooks R, Ruskin JN et al. Adenosine and the treatment of supraventricular tachycardia // Am J Med, 1992. V. 31. P. 714-718.
4. Steinbeck G, Reithmann C. Paroxysmal supraventricular tachycardia: preferential use of either adenosine or verapamil is dependent on the rate of tachycardia? // Eur Heart J, 2004. V. 25. P. 1277-1278.
5. Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia // ANN Emerg Med, 1991. V. 20. P. 717-721.
6. Glatter KA, Cheng J, Dorostkar P et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia // Circulation, 1999. V. 99. P. 1034-1040.
7. Резник А.В., Федоров В.В., Кокоз Ю.М. и соавт. Ион ные механизмы кардиотропного действия препарата III класса РГ-2 // Кардиология, 2003. №10. С. 76-82.
8. Levy S, Richard P. Using the right drug: a treatment algorithm for regular supraventricular tachycardias // Eur Heart J, 1997. V. 18. P. 27-32.
9. Manz M, Kuhl AJ, Lüderitz B. Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia // Z Kardiol, 1985. V. 74(9). P. 500-505.
10. Camm JA, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // Eur Heart J, 2010. V 19. P. 2369-2429.
11. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study // Circulation, 2004. V. 110. P. 1042-1046.
12. Daoud EG, Bogun F, Goyal R et al. Effect of atrial fibrillation on atrial refractoriness in humans // Circulation, 1996. V. 94. P. 1600-1606.
13. Розенштраух Л.В., Федоров В.В., Резник А.В. и соавт. Экспериментальное электрофизиологическое исследование препарата III класса РГ-2 // Кардиология, 2003. №9. С. 56-64.
14. Юричева Ю.А., Майков Е.Б., Соколов С.Ф и соавт. Первый опыт клинического применения нового антиаритмического препарата III класса ниферидила у больных с персистирующей формой фибрилляции и трепетания предсердий // Кардиология, 2011. №2. С. 55-64.
Review
For citations:
Mironov N.Yu., Golitsyn S.P., Sokolov S.F., Maykov E.B., Shlevkov N.B., Yuricheva Yu.A., Mareev Yu.V., Rozenshtraukh L.V., Chazov E.I. ELECTROPHYSIOLOGICAL AND ANTIARRHYTHMIC EFFECTS OF A NOVEL III CLASS ANTIARRHYTHMIC MANUFACTURED IN RUSSIA, NIFERIDIL COMMUNICATION II: ELECTROPHYSIOLOGICAL MECHANISMS OF ANTIARRHYTHMIC EFFECT OF NIFERIDIL IN PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIAS. Journal of Arrhythmology. 2012;70(70):21-26. (In Russ.)
Views:
130
Email this article 